chemotherapy/gin diare

Lyen an sove nan clipboard la

Chwazi kalite sòt

Paj 1 soti nan 5055 rezilta yo

Recommended guidelines for the treatment of chemotherapy-induced diarrhea.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

OBJECTIVE Management of chemotherapy-induced diarrhea (CID) has customarily involved symptomatic treatment with opioids in conjunction with supportive care. Alternatively, patients refractory to conventional therapy have been given octreotide, a somatostatin analogue. Although this agent has been

Amifostine, in a reduced dose, protects against severe diarrhea associated with weekly fluorouracil and folinic acid chemotherapy in advanced colorectal cancer: a pilot study.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

Fifty-two consecutive patients with advanced colorectal cancer who developed persistent diarrhea following chemotherapy with 5-fluorouracil despite dose reduction were treated with amifostine 800, 500 or 150 mg/m(2). The administered dose of 5-fluorouracil was significantly greater during amifostine

Resolution of refractory chemotherapy-induced diarrhea (CID) with octreotide long-acting formulation in cancer patients: 11 case studies.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

OBJECTIVE Subcutaneous (SC) octreotide has been shown to effectively relieve chemotherapy-induced diarrhea (CID) refractory to conventional therapy but requires t.i.d. injections. A microencapsulated, long-acting formulation (LAR) of octreotide has been developed for once-monthly intramuscular (IM)

The consequences of diarrhea occurring during chemotherapy for colorectal cancer: a retrospective study.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

OBJECTIVE Diarrhea is one of the dose-limiting toxicities associated with chemotherapy agents in treatment regimens for colorectal cancer. The objectives of this study were to analyze the impact of all grades of diarrhea on clinical decisions for patients receiving treatment for colorectal cancer by

Subcutaneous octreotide versus oral loperamide in the treatment of diarrhea following chemotherapy.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

Forty patients with chemotherapy-related diarrhea were randomized to receive (i) octreotide 0.5 mg three times per day s.c. or (ii) loperamide 4 mg three times per day p.o. until complete remission of diarrhea was achieved. In the octreotide group 80% of patients showed complete resolution of loose

Long-acting octreotide as secondary prevention of chemotherapy-induced diarrhea: proof of concept.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

BACKGROUND The aim of this study is to investigate the role of Octreotide LAR in secondary prevention in patients with chemotherapy-induced diarrhea. METHODS In this study, patients experiencing CID ≥ grade 2 received 30 mg long-acting octreotide as a monthly injection and the next chemotherapy dose

Control of chemotherapy-induced diarrhea with the synthetic enkephalin BW942C: a randomized trial with placebo in patients receiving cisplatin.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

Diarrhea commonly occurs following the administration of cisplatin. BW942C, a pentapeptide, is a synthetic enkephalin shown to control castor oil-induced and traveler's diarrhea. To assess the safety and efficacy of BW942C in controlling diarrhea caused by cisplatin, 30 adults with lung cancer who

Glutamine for chemotherapy induced diarrhea: a meta-analysis.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

The clinical efficacy of glutamine in the control of chemotherapy-induced diarrhea remains controversial. We conducted a meta-analysis, including as many randomized control trails (RCTs) as possible, to clarify the effectiveness of prophylactic glutamine in patients requiring

Octreotide acetate is efficacious and safe in children for treating diarrhea due to chemotherapy but not acute graft versus host disease.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

BACKGROUND The Common Toxicity Criteria of the National Cancer Institute evaluates diarrhea as an adverse event of chemotherapy administration. Acute graft versus host disease (aGVHD) causes diarrhea in allogeneic hematopoietic stem cell transplant patients. Guidelines for treating grade 3 and 4

Probiotics in preventing and treating chemotherapy-induced diarrhea: a meta-analysis.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

To systematically assess the safety and effectiveness of probiotics in preventing and treating chemotherapy-induced diarrhea (CID), so as to provide the evidence-based evidence for clinical practice.Electronic databases, including EMbase, Cochrane Library,

The Capsule Endoscopy Findings in S-1-induced Enteritis with Severe Diarrhea during Adjuvant Chemotherapy for Gastric Cancer (with Video).

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

Although S-1 chemotherapy is used widely as postoperative adjuvant chemotherapy for gastric cancer, some patients experience diarrhea during treatment. The patient was a 39-year-old woman who underwent distal gastrectomy for gastric cancer and who had started S-1 chemotherapy as postoperative

A multicenter, randomized trial of long-acting octreotide for the optimum prevention of chemotherapy-induced diarrhea: results of the STOP trial.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

Diarrhea is a well-recognized side effect of chemotherapy and can result in chemotherapy delay and/or dose reduction, potentially reducing the therapeutic benefit of treatment. Octreotide has been shown to be effective in controlling chemotherapy-induced diarrhea (CID). In this open-label,

Overview of chemotherapy-induced diarrhea.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

OBJECTIVE To provide a general overview of chemotherapy-induced diarrhea (CID) that will highlight the pathophysiology, incidence, and impact of this problem, as well as describe the oncology nurse's role in the management of CID. METHODS Primary and tertiary literature, the authors' clinical

Management of chemotherapy-induced diarrhea and constipation.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

This article reviews the incidence, etiology, pathophysiology, and assessment of diarrhea and constipation related to chemotherapy. Protocols for treatment are presented. The nurse's role in prevention, patient education, assessment, and treatment is emphasized.

Clinical implications of chemotherapy-induced diarrhea in patients with cancer.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

Diarrhea is a common, often dose-limiting toxicity associated with cancer chemotherapy treatment. However, the problem is not well recognized and frequently is not managed appropriately. The primary objectives of the current study were to describe the sociodemographic and clinical characteristics of

Antre nan paj
facebook nou an

Herbal & Natural Medicine

Baz done ki pi konplè remèd fèy medsin te apiye nan syans

Travay nan 55 lang
Geri èrbal te apiye nan syans
Remèd fèy rekonesans pa imaj
Kat entèaktif GPS - tag zèb sou kote (vini byento)
Li piblikasyon syantifik ki gen rapò ak rechèch ou an
Search remèd fèy medsin pa efè yo
Izeganize enterè ou yo ak rete kanpe fè dat ak rechèch la nouvèl, esè klinik ak rive

Tape yon sentòm oswa yon maladi epi li sou remèd fèy ki ta ka ede, tape yon zèb ak wè maladi ak sentòm li itilize kont.
* Tout enfòmasyon baze sou rechèch syantifik pibliye